Submission Deadline 10/25/2027
Fiscal Capacity $50,135,013
| Opportunity Number | PAR-25-104 |
|---|---|
| Agency | HHS-NIH11 |
| Application Deadline | 10/25/2027 |
| Award Amount | $50,135,013 |
| Status | Posted |
| Sector | Health |
| Cost Sharing | Not Required |
Fiscal Parameters & Taxonomy
Authority HHS-NIH11
Status Posted
Who Can Apply
Others (see text field entitled "Additional Information on Eligibility" for clarification) Public housing authorities/Indian housing authorities Independent school districts Native American tribal organizations (other than Federally recognized tribal governments) County governments Private institutions of higher education Small businesses City or township governments Public and State controlled institutions of higher education Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education State governments Special district governments Native American tribal governments (Federally recognized) For profit organizations other than small businesses Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Eligibility Intelligence
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Program Description
The purpose of this FOA is to facilitate well planned clinical trials across the cancer prevention and control spectrum aimed at improving prevention/ interception, cancer-related health behaviors, screening, early detection, healthcare delivery, management of treatment-related symptoms, supportive care, and the long-term outcomes of cancer survivors. Although the scientific literature or preliminary data may provide the rationale for conducting a clinical trial, investigators often lack critical information about the study population, accrual challenges, intervention, outcome/ endpoints, data/statistical challenges or operational risks necessary to finalize the trial protocol completely. These information gaps can result in multiple protocol changes before and after trial start-up, leading to the need for additional time and expenses that may prevent study completion. Further, the suitability and feasibility of new trial designs, which minimize infrastructure and reduce costs may need to be tested in the context of a particular intervention, at-risk group, symptom or venue. Preparatory studies may fill information gaps and address unknowns, improving trial design and knowledge of trial feasibility and thus saving NCI time and money.
CFDA Programs
93.399 Cancer Control
Agency Contact
Related Intelligence Guides
In-depth editorial guides covering this agency's programs, eligibility requirements, and application strategies.